Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2009

Open Access 01-12-2009 | Research article

Overexpression of human sperm protein 17 increases migration and decreases the chemosensitivity of human epithelial ovarian cancer cells

Authors: Fang-qiu Li, Yan-ling Han, Qun Liu, Bo Wu, Wen-bin Huang, Su-yun Zeng

Published in: BMC Cancer | Issue 1/2009

Login to get access

Abstract

Background

Most deaths from ovarian cancer are due to metastases that are resistant to conventional therapies. But the factors that regulate the metastatic process and chemoresistance of ovarian cancer are poorly understood. In the current study, we investigated the aberrant expression of human sperm protein 17 (HSp17) in human epithelial ovarian cancer cells and tried to analyze its influences on the cell behaviors like migration and chemoresistance.

Methods

Immunohistochemistry and immunocytochemistry were used to identify HSp17 in paraffin embedded ovarian malignant tumor specimens and peritoneal metastatic malignant cells. Then we examined the effect of HSp17 overexpression on the proliferation, migration, and chemoresistance of ovarian cancer cells to carboplatin and cisplatin in a human ovarian carcinoma cell line, HO8910.

Results

We found that HSp17 was aberrantly expressed in 43% (30/70) of the patients with primary epithelial ovarian carcinomas, and in all of the metastatic cancer cells of ascites from 8 patients. The Sp17 expression was also detected in the metastatic lesions the same as in ovarian lesions. None of the 7 non-epithelial tumors primarily developed in the ovaries was immunopositive for HSp17. Overexpression of HSp17 increased the migration but decreased the chemosensitivity of ovarian carcinoma cells to carboplatin and cisplatin.

Conclusion

HSp17 is aberrantly expressed in a significant proportion of epithelial ovarian carcinomas. Our results strongly suggest that HSp17 plays a role in metastatic disease and resistance of epithelial ovarian carcinoma to chemotherapy.
Appendix
Available only for authorised users
Literature
1.
Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 2000. CA Cancer J Clin. 2000, 50: 7-33. 10.3322/canjclin.50.1.7.CrossRefPubMed
2.
Choi JH, Choi KC, Auersperg N, Leung PC: Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells. Cancer Res. 2006, 66: 3912-3920. 10.1158/0008-5472.CAN-05-1785.CrossRefPubMed
3.
Chiriva-Internati M, Wang Z, Salati E, Timmins P, Lim SH: Tumor vaccine for ovarian carcinoma targeting sperm protein 17. Cancer. 2002, 94: 2447-2453. 10.1002/cncr.10506.CrossRefPubMed
4.
Yamasaki N, Richardson RT, O'Rand MG: Expression of the rabbit sperm protein Sp17 in COS cells and interaction of recombinant Sp17 with the rabbit zona pellucida. Mol Reprod Dev. 1995, 40: 48-55. 10.1002/mrd.1080400107.CrossRefPubMed
5.
Chiriva-Internati M, Grizzi F, Franceschini B, Hermonat PL, Bright RK, Bumm K, Dioguardi N, Kast WM: Is sperm protein 17 a useful target for tumor immunotherapy?. Blood. 2003, 102: 2308-2309. 10.1182/blood-2003-05-1747.CrossRefPubMed
6.
Chiriva-Internati M, Wang Z, Salati E, Bumm K, Barlogie B, Lim SH: Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma. Blood. 2002, 100: 961-965. 10.1182/blood-2002-02-0408.CrossRefPubMed
7.
Straughn JM, Shaw DR, Guerrero A, Bhoola SM, Racelis A, Wang Z, Chiriva-Internati M, Grizzle WE, Alvarez RD, Lim SH, Strong TV: Expression of sperm protein 17 (Sp17) in ovarian cancer. Int J Cancer. 2004, 108: 805-811. 10.1002/ijc.11617.CrossRefPubMed
8.
Gupta G, Sharma R, Chattopadhyay TK, Gupta SD, Ralhan R: Clinical significance of sperm protein 17 expression and immunogenicity in esophageal cancer. Int J Cancer. 2007, 120: 1739-1747. 10.1002/ijc.22463.CrossRefPubMed
9.
Bumm K, Grizzi F, Franceschini B, Koch M, Iro H, Wurm J, Ceva-Grimaldi G, Dimmler A, Cobos E, Dioguardi N, Sinha UK, Kast WM, Chiriva-Internati M: Sperm protein 17 expression defines 2 subsets of primary esthesioneuroblastoma. Hum Pathol. 2005, 36: 1289-1293. 10.1016/j.humpath.2005.08.023.CrossRefPubMed
10.
Grizzi F, Chiriva-Internati M, Franceschini B, Bumm K, Colombo P, Ciccarelli M, Donetti E, Gagliano N, Hermonat PL, Bright RK, Gioia M, Dioguardi N, Kast WM: Sperm protein 17 is expressed in human somatic ciliated epithelia. J Histochem Cytochem. 2004, 52: 549-554.CrossRefPubMed
11.
Wang Z, Zhang Y, Ramsahoye B, Bowen D, Lim SH: Sp17 gene expression in myeloma cells is regulated by promoter methylation. British J Cancer. 2004, 91: 1597-1603.
12.
Li FQ, Yang AL, Miao JW, Zhang CH, Wu B, Zhang XH: Preparation and characterization of the monoclonal antibody against human sperm protein 17. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2006, 22: 638-640. in ChinesePubMed
13.
Simpson AJ, Caballero OL, Jungbluth A, Chen Y-T, Old LJ: Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005, 5: 615-625. 10.1038/nrc1669.CrossRefPubMed
14.
Scanlan MJ, Simpson AJ, Old LJ: The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 2004, 4: 1-PubMed
15.
Chiriva-Internati M, Wang Z, Salati E, Wroblewski D, Lim SH: Successful generation of sperm protein 17 (Sp17)-specific cytotoxic T lymphocytes from normal donors: implication for tumour-specific adoptive immunotherapy following allogeneic stem cell transplantation for Sp17-positive multiple myeloma. Scand J Immunol. 2002, 56: 429-433. 10.1046/j.1365-3083.2002.01138.x.CrossRefPubMed
16.
Chiriva-Internati M, Wang Z, Pochopien S, Salati E, Lim SH: Identification of a sperm protein 17 CTL epitope restricted by HLA-A1. Int J Cancer. 2003, 107: 863-865. 10.1002/ijc.11486.CrossRefPubMed
17.
Dadabayev AR, Wang Z, Zhang Y, Zhang J, Robinson WR, Lim SH: Cancer immunotherapy targeting Sp17: when should the laboratory findings be translated to the clinics?. Am J Hemato. 2005, 80: 6-11. 10.1002/ajh.20415.CrossRef
18.
De Jong A, Buchli R, Robbins D: Characterization of sperm protein 17. in human somatic and neoplastic tissue. Cancer Lett. 2002, 186: 201-209. 10.1016/S0304-3835(02)00350-6.CrossRefPubMed
19.
Grizzi F, Chiriva-Internati M, Franceschini B, Hermonat PL, Soda G, Lim SH, Dioguardi N: Immunolocalization of sperm protein 17 in human testis and ejaculated spermatozoa. J Histochem Cytochem. 2003, 51: 1245-1248.CrossRefPubMed
20.
Lim SH, Wang Z, Chiriva-Internati M, Xue Y: Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma. Blood. 2001, 97: 1508-1510. 10.1182/blood.V97.5.1508.CrossRefPubMed
21.
Nakazato T, Kanuma T, Tamura T, Faried LS, Aoki H, Minegishi T: Sperm protein 17 influences the tissue-specific malignancy of clear cell adenocarcinoma in human epithelial ovarian cancer. Int J Gynecol Cancer. 2007, 17: 426-432. 10.1111/j.1525-1438.2007.00815.x.CrossRefPubMed
22.
Wen Y, Richardson RT, O'Rand MG: Processing of the sperm protein SP17 during the acrosome reaction and characterization as a calmodulin binding protein. Biochem J. 1999, 357: 25-31. 10.1042/0264-6021:3570025.CrossRef
23.
Lacy HM, Sanderson RD: Sperm protein 17 is expressed on normal and malignant lymphocytes and promotes heparan sulfate mediated cell-cell adhesion. Blood. 2001, 98: 2160-2165. 10.1182/blood.V98.7.2160.CrossRefPubMed
24.
Frayne J, Hall L: A re-evaluation of sperm protein 17 (SP17) indicates a regulatory role in an A-kinase anchoring protein complex rather than a unique role in sperm-zona pellucida binding. Reproduction. 2002, 124: 767-774. 10.1530/rep.0.1240767.CrossRefPubMed
25.
Lea IA, Widgren EE, O'Rand MG: Association of sperm protein 17 with A-kinase anchoring protein 3 in flagella. Reprod Biol Endocrinol. 2004, 2: 57-63. 10.1186/1477-7827-2-57.CrossRefPubMedPubMedCentral
26.
Wen Y, Richardson RT, Widgren EE, O'Rand MG: Characterization of SP17: a ubiquitous three domain protein that binds heparin. Biochem J. 2001, 206: 113-22.
Metadata
Title
Overexpression of human sperm protein 17 increases migration and decreases the chemosensitivity of human epithelial ovarian cancer cells
Authors
Fang-qiu Li
Yan-ling Han
Qun Liu
Bo Wu
Wen-bin Huang
Su-yun Zeng
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-9-323

Other articles of this Issue 1/2009

BMC Cancer 1/2009 Go to the issue

Research article

Nuclear receptor coregulator SNP discovery and impact on breast cancer risk

Research article

The presence of postmenopausal bleeding as prognostic parameter in patients with endometrial cancer: a retrospective multi-center study

Research article

A mammalianized synthetic nitroreductase gene for high-level expression

Research article

Concurrent intra-arterial carboplatin administration and radiation therapy for the treatment of advanced head and neck squamous cell carcinoma: short term results

Research article

Measuring prostate-specific quality of life in prostate cancer patients scheduled for radiotherapy or radical prostatectomy and reference men in Germany and Canada using the Patient Oriented Prostate Utility Scale-Psychometric (PORPUS-P)

Research article

Factors associated with improved survival among older colorectal cancer patients in the US: a population-based analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits